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Hepatic artery chemotherapy was given to 36 patients, using totally implantable devices consisting ofa port
and external pump. Twenty-seven patients had inoperable liver metastases ofcolorectal origin. The infusion
system was inserted by laparotomy into the hepatic artery via the gastroduodenal artery. There was no
operative mortality. Thirteen infusion systems could not be used for chemotherapy due to dislodgement,
early death and lack of follow-up. FUdR was infused every two weeks. There were minor local
complications like thrombosis of the system and dislodgement of the port. Toxic effects could be managed
by reducing the dose. Response to chemotherapy was evaluated by survival, clinical condition, CEA,
ultrasound and CT six months after onset of arterial chemotherapy. Ten/twenty-three patients (43%)
responded to therapy, eight ofthem died on the average 19 months after initial chemotherapy. Six patients
were non-responders, seven had stable disease. Five/ten patients developed extrahepatic metastases. Mean
survival time was 13.1 months, mean interval until relapse 10.6 months.
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INTRODUCTION:
80% ofpatients who succumb from colorectal cancer die ofhepatic metastases. So far
hepatic resection has been the only curative intervention: The five year survival rate is
25%2 and 330/03 Nevertheless, the chances of curative resection are no higher than
8%4
To help in the incurable state ofinoperable liver metastases, palliative methods have
been developed:
1. Systemic chemotherapy with a maximum response of 20%5’6.
2. Regional hepaticchemotherapy has been introduced, presupposing that perfusion
of the liver metastases is predominantly by the hepatic artery7’8. Regional hepatic
artery chemotherapy was first performed via percutaneous angiography catheters9’.
However, external catheter-related complications, such as dislodgement, infection or
thrombosis were limiting factors with this procedure. Since totally implantable devices
11 12 with port or pump have been introduced this method has become widely accepted.
Isolated perfusion ofthe liver has been performed3 but is not commonly used. On the
other hand, methods to reduce perfusion of hepatic metastases such as hepatic artery
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ligation14 have been tried, or embolization with microspheres5. As an additional
measure, microspheres beating cytostatic drugs have been used6. In the absence of
palliative procedures, life expectance is as follows: 3.1 months7, 4 monthss, 11
months9, and 13.8 months2.
Being aware of the hopeless condition of these patients, we use regional hepatic
chemotherapy. Liver metastases ofnon-colorectal origin as well as primary tumors of
the liver are also included in this series as has been reported by other authors2,22,23.
PATIENTS AND METHODS:
Thirty-six totally implantable infusion systems were inserted between June 1983 and
July 1988 (Table 1.) In one patient the catheter system was implanted but metastases
could not be confirmed by histological examination. The diagnosis "liver metastases"
was assessed by laparotomy (n 16), ultrasound (n 10), ultrasound and CT (n 4),
CT (n 4) and scintigram (n 1). Fourteen patients received the implantable catheter
system at the same time as the resection of the primary tumor and 22 were implanted
three to 48 months following primary surgery.
Surgical Technique and Infusion Chemotherapy:
Indications for hepatic arterychemotherapy were hepatic involvement ofno more than
70%, expected survival time more than three months and no extrahepatic metastases.
The gastroduodenal artery was isolated and the catheter introduced. The distal
gastroduodenal artery as well as the right gastric artery and every visible branch were
ligated to avoid perfusion of stomach, duodenum and pancreas. The catheter was
attached to the port. The latter was fixed in a subcutaneous pouch above the left costal
arch. In 18 patients cholecystectomy was carried out, in seven cases this had been
performed previously. Liver perfusion was checked postoperatively by radioisotopes
(Xe
133 or Technetium99) and angiography (DSA).
Hepatic artery chemotherapy using FUdR was started 10 to 14 days after
implantation of the infusion system. 0.3 mgJkg body weight/day FUdR was
administered via an external pump (PharmaciaK) two weeks therapy, two-week
interval without treatment. These cycles were repeated for six months after which
response to therapy was assessed. Response to therapy was defined in terms of a 50%
decrease of tumor volume in ultrasound or CT and/or a 30% decrease ofCEA levels
according to WHO definition. Patients were examined every two weeks. In case of
adverse side effects, the dose was reduced to 0.2 or 0.1 mg FUdR/kg/day or the regimen
changed to one week of therapy and three week intervals.
Table 1 Patients
Age 64 (36-81) years
Sex 16 male, 20 female
Liver metastases 31
colorectal 27
breast 2
uterus
choroid membrane
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Patients who did not respond to FUdR or relapsed after an initial response were
treated with MitomycinC 14mg/m2 body surface, sometimes combined with SpherexR
(microspheres). Hepatocellular carcinomas were treated by Mitoxantrone 14 mg/m2,
increasing the dose to 20 mg/m2.
RESULTS
No patient died after insertion ofhepatic artery infusion systems. One system had to be
removed because of bowel obstruction following sigmoid resection. One system was
not used because of absence of hepatic metastases. In four patients (11%) a
dislodgement of the catheter was observed at control angiography, implying that only
the left liver lobe (n= 1) or the stomach, pancreas and/or the spleen (n= 3) were
perfused. There was one infection of the port (3%), requiring the removal of the
system. Two patients did not get chemotherapy because of rapid deterioration: One
metastatic liver disease due to breast cancer, one hepatocellular carcinoma in a
cirrhotic liver. For three patients who were operated on during the last six months, the
time has been too short for evaluation. Two patients stopped chemotherapy within the
first three months and they cannot be evaluated. Twenty-three cases remain for
evaluation.
Complications related to the totally implanted system:
Eight thromboses, four of them treated by streptokinase, four by surgical revision
including shortening of the catheter and/or change of the port. All these systems have
been working smoothly since these interventions. Two ports had to be revised because
of dislodgement.
Adverse side effects ofarterial chemotherapy:
Pathologic liver function tests were found in more than half of our patients, tests
improved rapidly after reducing the dose ofFUdR. Only one severe chemical hepatitis
was observed. Three patients developed duodenal ulcer, six reported severe
gastrointestinal symptoms. There was no cholecystitis and no sclerosing cholangitis in
this series. Thirteen patients were free of any side effects during regional
chemotherapy.
Response to chemotherapy was evaluated six months after initiation, checking
survival, clinical condition, CEA levels, ultrasound and CT (Table 2). Ten/twenty-
three (43%) of our patients were considered responders. Nine of these responders
belong to the colorectal group, one had liver metastases due to uterine carcinoma. Six
were non-responders (Table 2). Four of these patients had a colorectal primary
carcinoma, one choroid membrane carcinoma and one a hepatoma. Disease was
assessed as stable in seven patients (Table 2). Five of these had metastases due to
colorectal cancer, one due to breast cancer and one due to hepatoma. Six/ten
responders showed a marked decrease ofCEA levels from 343(6-1200) ng/ml before
hepatic chemotherapy to 53(3.2-100.8) ng/ml at six months (Table 2). Three/ten
patients had a complete remission by ultrasound, 4/10 by CT (Figures and 2).
Nevertheless, five out of ten developed extrahepatic metastases although they had
responded to therapy at six months: four had lung metastases and one had brain
metastasis.24
Table 2 Results
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Responder Non-Responder Stable disease
n 10/23 43% 6/23 7/23
Survival:
a. alive 2 after 11 &27 mos.
b. dead 8 after 19 (12-29) mos.
CEA 30% drop 6/10
Ultrasound 50% drop 3/10
CT 50% drop 4/10
Extrahepatic disease 5/10
Mean period between onset ofchemotherapy and relapse
Mean survival time
after 5 mos. 6 after 8 (6-10) mos.
5 after 4 (2-7) mos. after 7 mos.
10.6 (6-16) mos.
13.1 (2-27) mos.
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Figure 2 CT four months after the onset ofchemotherapy
DISCUSSION:
The goals of regional chemotherapy are to maximize concentration of chemo-
therapeutic drugs. The superiority of hepatic artery chemotherapy compared to the
portal vein route was reported in a controlled study24. 5-Fluro-2-deoxyuridine
(floxuridine, FUdR) is the ideal drug for this purpose because of its high extraction by
the liver during the first pass (98%) in comparison to 5-Fluorouracil with a maximum
of 50% extraction2. Consequently, most authors used FUdR12’21’:6 instead of 5-
FU22’27. Some21’28 added Mitomycin C in case of tumor relapse or non-response to
FUdR. Discussion ofFUdR administration as bolus injection vs. continuous infusion
favours continuous administration by pump1’2’2’28.
Most authors suggest angiography lecause of possible anomalies of the hepatic
o 21.29 artery in 12- 19 Vo The catheter is introduced via the gastroduodenal artery but in
appropriate cases the splenic
26 or the gastroepiploic artery (two ofour own cases) may
be cannulated. Nevertheless, the distal gastroduodenal, the fight gastric and also every26 A. TUCHMANN ETAL.
visible branch supplying stomach, duodenum and pancreas should be ligated.
Cholecystectomy to avoid chemical cholecystitis has been performed in every case3,
seldom2s and occasionally (our own patients). Cohen2s and our group did not observe
subsequent cholecystitis. Nevertheless, wenow perform cholecystectomy in every case.
Perfusion of the liver may be checked intraoperatively by fluorescein1,26,3 and
postoperatively by radioisotopes (Te99)29’2,
ur own group or digital subtraction
angiography via the port23, ow group. In four of our cases the perfusion was
misdirected, once to the left liver lobe and in three patients to pancreas and spleen.
The operative mortality is negligible in most reports. There was no postoperative
death in our own series. Among our cases there was clotting ofthe infusion system and
dislodgement ofthe port as well as one infection but local complications do not play an
important role in totally implantable infusion systems.
o o 24 The overall response rate amounted to 43 ’A, comparable wth Daly s 41 ’
and
Encke’s 42%23. Niederhuber2, Balch2 and Rammingr reported much higher response
rates ranging between 832’2 and 88% . Thirlwel122 and Chang 3o reported response
rates of60 and 62%, respectively. Nevertheless, response rates cannot be compared as
the cases included in the studies were too different: 1. Liver involvement less than
50%21; 2. Presence ofextrahepatic disease28,32; 3. Different chemotherapy regimens and
4. Different criteria of assessment: Survival, clinical condition, sonography, CT and
CEA.
Mean survival time could not be markedly prolonged by hepatic artery
chemoinfusion: 11.5 to 13 months mean survival in most recent studies1,23,38, ourown eases.
A mean survival time of 24 months 2 could not be observed elsewhere. The mean
interval before tumor relapse was seven to nine months22’23’24’3 compared to 10.6
months in our own patients.
Although there are no systemic side effects of regional chemotherapy23, the
disadvantage of hepatic artery chemotherapy is the toxicity to liver, stomach,
duodenum and pancreas. Severe chemical hepatitis was seen in only one instance here,
o 23 24 30 but has constituted 38 to 79 % in the literature Biliary sclerosis was observed in
15%23 and 21%30, gastroduodenal ulcer in 3/23 (13%) of our patients, and 17% 3o or
31% in other series. These toxic side effects depend on the FUdR dose23’26; chemical
hepatitis is always reversible The dose always has to be reduced in protracted
treatment23,30, our ownexrden. There was no case ofbiliary sclerosis in our patients, 13/23
subjects had no complaints during FUdR chemoinfusion. We attribute this to an early
dose reduction or to a changed cycle consisting ofone week therapy and a three week
interval. Schlag27who worked with 5-FU did not observe any ofthe adverse side effects
described in connection with FUdR.
A major problem ofregional hepatic chemotherapy constitutes the developement of
extrahepatic tumors, mainly metastatic involvement of the lung. Extrahepatic disease
was reported in 45 to 62% 1,23,30 and must be expected in effective chemotherapy of the
liver. In our series 5/10 patients with positive response to therapy contracted
extrahepatic disease.
Patients have to be selected carefully for this new palliative tumor therapy as a recent
prospective randomized study comparing intraarterial with intravenous
30 chemotherapy for liver metastases showed there were different response rates: 62%
(i.a.) vs. 17% (i.v.) but no difference in life expectancy: Two-year survival rate 22 vs.
15%. The disease-free interval was seven and nine months respectively. The goal to be
achieved with hepatic artery infusion chemotherapy should be:
1. a less toxic cytostatic agent in order to avoid complications to the bile ducts, the
stomach, the duodenum and the pancreas,HEPATIC ARTERY INFUSION CHEMOTHERAPY 27
2. a combination with systemic chemotherapy to avoid extra-hepatic metastases and
3. a combination with surgery, yielding inoperable metastases operable by regional
chemotherapy prior to liver resection.
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INVITED COMMENTARY
The advent of the technology for hepatic artery infusion using an implantable system
with a port has certainly contributed to the management of patients with advanced
metastatic diseases of the liver and a considerable number of papers have been
published. However, a high incidence rate of complications such as dislodgement of
clogging of the catheter, infection around the port, mis-directed perfusion and side
effects ofanti-tumor agents is a serious problem inherent to this technique. In fact, it is
an unacceptable problem, if chemotherapy has to be discontinued because of these
complications, especially in the patients in whom the catheter was surgically inserted
into the hepatic artery.
In our Department, one-shot transcatheter infusion of an anti-tumor agent
suspended in oil (Nimustine-Lipiodol suspension) has been indicated as the method of
choice in these cases for the last 3 years and a favorable result has been obtained.
Nimustine, a derivative ofNimustine hydrochloride, was suspended in Lipiodol using
ultrasonic agitation and used in experimental animals andhuman subjects. In 2 out of5
cases with hepatoma which responded to treatment, hepatic lobectomy was carried out
some days later. In these cases, although a tiny cancerous lesion was histologically
detected at the edge in the subcapsular region a surrounding cystic lesion replaced the
tumor, an obvious effect of this agent. In the remainder, administration of anti-tumor
agent has been repeated at various intervals when tumor-markers become re-elevated.
Our previous experimental study found that the anti-tumor agent suspended in
Lipiodol is gnore selectively accumulated and more slowly released in tumor tissue,
resulting in a long-acting effect, compared with that of an anti-tumor agent such as
FUdR dissolved in water. Moreover, another advantage to using Lipiodol is that
information necessary for follow-up studies can be easily obtained, because the lesion
is clearly delineated with Lipiodol.
The patients in which this type of treatment is indicated are, in general, in a grave
condition. Therefore, the type of anti-tumor agent and method of its administration
should be seriously considered before it is given.
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